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New & Noteworthy 18 
The ScheBo Pancreatic Elastase 1 Stool Test is widely used to assess pancreatic exocrine 19 
function yet its molecular targets have been poorly defined. Here we demonstrated that among 20 
the human pancreatic proteinases the test measures the elastase isoform CELA3B and, to a lesser 21 
extent, CELA3A. Genetic variants of the human CELA3 isoforms have no significant effect on 22 
test performance. 23 
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ABSTRACT 27 
Determination of fecal pancreatic elastase content by ELISA is a reliable, non-invasive clinical 28 
test for assessing exocrine pancreatic function. Despite the widespread use of commercial tests, 29 
their exact molecular targets remain poorly characterized. This study was undertaken to clarify 30 
which human pancreatic elastase isoforms are detected by the ScheBo Pancreatic Elastase 1 31 
Stool Test and whether naturally-occurring genetic variants influence the performance of this 32 
test. Using recombinantly expressed and purified human pancreatic proteinases we found that the 33 
test specifically measured chymotrypsin-like elastases 3A and 3B (CELA3A and CELA3B) 34 
while CELA2A was not detected. Inactive proelastases, active elastases and autolyzed forms 35 
were detected with identical efficiency. CELA3B gave approximately four times higher signal 36 
than CELA3A and we identified Glu154 in CELA3B as the critical determinant of detection. 37 
Common genetic variants of CELA3A and CELA3B had no effect on ELISA signal strength 38 
with the exception of the CELA3B variant W79R which increased detection by 1.4-fold. Finally, 39 
none of the human trypsin and chymotrypsin isoforms were detected. We conclude that the 40 
ScheBo Pancreatic Elastase 1 Stool Test is specific for human CELA3A and CELA3B, with 41 
most of the ELISA signal attributable to CELA3B. 42 
  43 
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INTRODUCTION 44 
Diseases of the pancreas that result in loss of functional acinar cells can compromise digestive 45 
enzyme production and eventually lead to maldigestion. Clinical laboratory tests that quantify 46 
decreased digestive enzyme output can aid in the diagnosis of pancreatic insufficiency. The most 47 
widely used tests measure levels of a pancreatic elastase enzyme in the stool [1, 7, 8, 12, 13, 15, 48 
18, 19, 20, 23, 30, 32, 44]. The chymotrypsin-like elastases (CELAs) are digestive serine 49 
proteinases secreted by the pancreas in multiple isoforms. CELA1 was first described by 50 
Hungarian scientists Baló and Banga (1949) as an enzyme activity in the pig pancreas capable of 51 
hydrolyzing insoluble elastin [3, 4]. Due to its cationic character, CELA1 can absorb to the 52 
surface of the negatively charged elastin fibers and cleave multiple Ala-Ala and Ala-Gly peptide 53 
bonds [9, 10, 43]. Despite its name, CELA1 is not a specific elastin-degrading enzyme and it 54 
readily digests a variety of dietary protein substrates. The primary specificity pocket of CELA1 55 
accommodates small (Ala, Ser) and aliphatic (Ile, Leu, Met, Val) amino-acid side-chains at the 56 
so-called P1 position of its substrates (Schechter-Berger nomenclature [29] of proteinase-57 
substrate interactions, where P1-P1’ corresponds to the scissile peptide bond) [5 and references 58 
therein]. Curiously, while the human CELA1 gene appears to be potentially functional, it is not 59 
expressed in the pancreas due to evolutionary mutations in its promoter and enhancer regions 60 
[26, 41]. A second pancreatic elastase (CELA2) was identified based on its ability to solubilize 61 
elastin [17, for a complete list of references see 5]. Unlike CELA1, this elastase exhibits 62 
chymotrypsin-like P1 specificity and prefers to cleave after aromatic (Tyr, Phe) and aliphatic 63 
(Leu, Met) P1 amino-acids [6, 17, 34]. In humans evolutionary duplication of CELA2 gave rise 64 
to the CELA2A and CELA2B genes. Even though both genes are expressed at the mRNA level 65 
[14], only the CELA2A enzyme is functional as CELA2B seems to have accumulated 66 
inactivating evolutionary mutations [35]. The CELA2A content of pancreatic juice corresponds 67 
to about 10% of total protein [24]. 68 
 Arguably, CELA3 has the most interesting history and characteristics among the human 69 
elastases. This elastase gene is also duplicated in humans and the two closely related isoforms 70 
were designated as CELA3A and CELA3B [31, 42]. Both are expressed in the pancreas at 71 
comparable mRNA and protein levels [31, 42]. Substrate specificity of human CELA3A and 72 
CELA3B appear to be similar to that of porcine CELA1, broadly directed toward aliphatic P1 73 
side chains [5 and references therein]. CELA3B was first described in 1975 as protease E, an 74 
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anionic pancreatic proteinase devoid of elastolytic activity [21]. A subsequent study in 1976 75 
isolated human CELA3B and CELA2A and designated these enzymes as elastase 1 and elastase 76 
2, respectively [17]. For reasons that remain unclear, the authors found that CELA3B was 77 
capable of solubilizing elastin; an erroneous observation which at the time justified the elastase 1 78 
name. Finally, in a number of studies starting in 1982, Sziegoleit and coworkers characterized a 79 
so-called cholesterol-binding protein with proteolytic activity, which eventually turned out to 80 
correspond to CELA3B [36, 37, 39]. These authors also determined that the CELA3B content of 81 
human pancreatic juice accounts for 4-6% of total protein [36]. Thus, the combined levels of 82 
CELA3A and CELA3B are similar to those of CELA2A. Spurred by the observation that 83 
CELA3B suffers no proteolytic degradation during intestinal transit and appears in the stool in 84 
high concentrations [36], ELISA tests have been developed for the detection of stool elastase and 85 
their clinical utility in the diagnosis of pancreatic insufficiency has been demonstrated [7, 8, 12, 86 
15, 18, 19, 20, 23, 30, 32]. One of the most widely used assays is the Pancreatic Elastase 1 Stool 87 
Test by ScheBo Biotech AG (Giessen, Germany), which utilizes two monoclonal antibodies 88 
raised against CELA3B to measure enzyme levels. However, it remains unclear whether the test 89 
also detects other elastases, CELA3A in particular, and to what extent the homologous 90 
pancreatic trypsins and chymotrypsins might interfere with the assay. More importantly, the 91 
potential confounding effect of natural CELA3 variants on test performance has never been 92 
evaluated. In the present study, we set out to fill these knowledge gaps and using well-defined 93 
recombinant pancreatic proteinases we characterized the detection specificity of the ScheBo 94 
ELISA test. 95 
 96 
MATERIALS and METHODS 97 
Materials. The ScheBo Pancreatic Elastase 1 Stool Test was purchased from the manufacturer. 98 
For some of the experiments we used the ScheBo Pancreatic Elastase 1 Serum Test which 99 
contains essentially the same ELISA components. 100 
Nomenclature. Coding DNA numbering starts with the first nucleotide of the translation initiator 101 
codon which was designated c.1. Amino acid residues were numbered starting with the initiator 102 
methionine of the primary translation product. Note that the CELA3A and CELA3B genomic 103 
reference sequences (chromosome 1 primary assembly, NC_000001.11) contain the minor allelic 104 
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variants G241A and W79R, respectively. In the present study, we used the common alleles at 105 
these positions as the reference and designated G241A and W79R as the minor variants. 106 
Plasmid construction and mutagenesis. Expression plasmids for human elastases CELA2A, 107 
CELA3A, CELA3B and chymotrypsins CTRB1, CTRB2, CTRC and CTRL1 constructed in the 108 
pcDNA3.1(-) vector [33 and references therein] and for human trypsins PRSS1, PRSS2 and 109 
PRSS3 in the pTrapT7 vector were described previously [16, 27, 28, 40]. The plasmids contain 110 
the coding DNA for the proenzyme (zymogen) form of the indicated pancreatic proteinases. 111 
Mutations in CELA3A and CELA3B were introduced by overlap extension PCR mutagenesis. 112 
The coding DNA for autolyzed forms of CELA3B carrying 9 His residues at their C terminus 113 
was created by gene synthesis and cloned into the pcDNA3.1(-) plasmid using EcoRI and 114 
BamHI restriction sites. In the CELA3B-9del construct the N-terminal 9 amino acids from Tyr18 115 
to Ser26 were deleted. In the CELA3B-13del construct the N-terminal 13 amino acids from 116 
Tyr18 to Val30 were removed. 117 
Cell culture and transfection. For small scale expression studies, HEK 293T cells were grown in 118 
six-well tissue culture plates (1.5×106 cells per well) in Dulbecco's Modified Eagle Medium 119 
(DMEM) supplemented with 10% fetal bovine serum, 4 mM glutamine and 1% 120 
penicillin/streptomycin, at 37 oC. Transfections were performed with 4 µg expression plasmid 121 
with 10 µL Lipofectamine 2000 in 2 mL DMEM. After overnight incubation cells were rinsed 122 
and covered with 2 mL Opti-MEM Reduced Serum Medium. The conditioned media were 123 
harvested after 48 h. 124 
Purification of pancreatic proteinases. Human proelastases and chymotrypsinogens were 125 
expressed in transiently transfected HEK 293T cells and purified from the conditioned medium 126 
through their C-terminal His tags by nickel-affinity chromatography, as reported previously [33]. 127 
Human trypsinogens were expressed in E. coli as insoluble inclusion bodies. Refolding and 128 
purification on immobilized ecotin were performed according to our published protocol [16, 27, 129 
28, 40]. Concentrations of proenzyme solutions were determined on the basis of their UV 130 
absorbance at 280 nm using the following extinction coefficients, calculated with the web-based 131 
ProtParam tool (in M-1·cm-1 units): CELA2A 73,505; CELA3A 76,025; CELA3B 74,535; 132 
CELA3B mutant W79R 69,035; CTRB1 and CTRB2 47,605; CTRC 64,565; PRSS1 37,525; 133 
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PRSS2 38,890; PRSS3 41,535. Proteinase solutions were diluted to 1 nM working stocks in 134 
assay buffer (0.1 M Tris-HCl (pH 8.0), 1 mM CaCl2 and 0.05% Tween 20). 135 
Expression and purification of autolyzed CELA3B forms. The CELA3B-9del and CELA3B-136 
13del constructs were produced in HEK 293T cells and purified by nickel-affinity 137 
chromatography as described for the wild-type proenzyme [33]. N-terminal sequencing of the 138 
purified proteins revealed that ~90% of the CELA3B-9del preparation contained the expected N 139 
terminus of Ser27 and minor contaminants with N-terminal amino acids of Asn31 (5%) and 140 
Glu33 (5%). The purified CELA3B-13del contained an approximately 50-50% mixture of two 141 
forms; one with the expected N terminus of Asn31 and another species with an N-terminal 142 
Glu33, indicating that the signal peptidase processed this construct at two sites. This preparation 143 
was suitable for the purpose of our experiments and further purification was not attempted. 144 
Enzyme activity measurements. Enzymatic activity of human CELA3A and CELA3B in the 145 
conditioned medium of transfected cells was determined using the Suc-Ala-Ala-Pro-Ala-p-146 
nitroanilide substrate [5]. To activate proelastases, aliquots of conditioned media (100 µL) were 147 
supplemented with 10 µL of 1 M Tris-HCl (pH 8.0) and 1 µL 0.1 M CaCl2 and incubated with 148 
100 nM human cationic trypsin at 37 oC for 30 min (final concentrations). Activated elastases 149 
(20 μL) were then mixed with 175 μL assay buffer (0.1 M Tris-HCl (pH 8.0), 1 mM CaCl2, 150 
0.05% Tween 20) and elastase activity was measured by adding 5 μL of 6 mM substrate. The 151 
increase in absorbance at 405 nm was followed for 5 min in a microplate reader at 22 oC. Rates 152 
of substrate cleavage were calculated from the linear portion of the curves and expressed in 153 
mOD/min units. 154 
ELISA assays. Detection of human pancreatic proteinases by the ScheBo test was performed 155 
according to the manufacturer’s instructions with the ready-to-use reagents supplied, as follows. 156 
The 5× wash buffer (phosphate buffered saline (pH 7.2) with unspecified detergent) stock was 157 
diluted with water before use. Aliquots (50 µL) of purified proteinases or conditioned media 158 
diluted in assay buffer (0.1 M Tris-HCl (pH 8.0), 1 mM CaCl2, 0.05% Tween 20) were added to 159 
the ELISA strips containing an immobilized anti-elastase antibody (Figure 1). As blank, 50 µL 160 
assay buffer was used. After 30 min incubation at 22 oC, the enzyme solutions were removed 161 
from the wells. The wells were rinsed three times for 2 min each with 250 µL wash buffer. An 162 
aliquot (50 µL) of a biotinylated anti-elastase antibody complexed with peroxidase-conjugated 163 
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streptavidin was added to the wells and incubated for 30 min in the dark at 22 oC. The antibody 164 
solution was discarded and the wells were rinsed three times for 2 min each with 250 µL wash 165 
buffer. For color development, 100 µL 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) 166 
(ABTS) peroxidase substrate solution was added and incubated in the dark or 20 min at 22 oC. 167 
The reaction was terminated by adding 100 µL stop solution and incubating for 10 min. The dark 168 
green ELISA signal (absorbance) was measured in a plate reader at 405 nm. All assays were 169 
performed in duplicates. Data points plotted represent absorbance readings corrected for the 170 
average of two blank values. 171 
 172 
RESULTS 173 
The ScheBo Pancreatic Elastase 1 Stool Test detects elastase 3 isoforms CELA3A and 174 
CELA3B. To determine the specificity of the ScheBo test, we recombinantly expressed and 175 
purified human pancreatic serine proteinases and performed ELISA assays according to the 176 
manufacturer’s instructions. Elastases CELA3A and CELA3B were tested at 100 pM final 177 
concentration while all other proteinases were tested at the 10-fold higher 1 nM concentration 178 
(Figure 2). We obtained strong signals for CELA3A and CELA3B whereas none of the other 179 
proteinases was detected to a significant extent. 180 
Proelastases, active elastases and autolyzed elastase forms are measured with equal 181 
efficacy. To characterize the detection of CELA3A and CELA3B by the ScheBo test in a more 182 
quantitative manner, we performed the ELISA assay using elastases over a concentration range 183 
from 20 to 200 pM. As shown in Figure 3A, CELA3B was detected on average 4.3-fold better 184 
(range 3.4 – 5.1-fold) than CELA3A over the concentration range tested. Identical signals were 185 
obtained when proelastases were compared to active elastases indicating that the test measures 186 
the zymogen and active forms with equal efficacy (Figure 3A). Autolyzed forms of CELA3B 187 
missing either 9 amino acids (9del) or 13 amino acids (13del) from the N terminus also produced 188 
ELISA signals identical to that of the intact CELA3B proelastase (Figure 3B). Since these results 189 
indicate that the ScheBo test does not discriminate between proelastase, active elastase and 190 
autolyzed elastase, in all subsequent experiments we used the proelastase forms of CELA3A and 191 
CELA3B. In a control experiment we also ruled out the unlikely confounding effect of the His 192 
tag on elastase expression and detection by the ScheBo test. Although data are not shown, tagged 193 
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and untagged forms of CELA3A and CELA3B were secreted to comparable levels into the 194 
conditioned medium of transfected cells and gave identical ELISA signals. 195 
Effect of CELA3A and CELA3B genetic variants on the performance of the ScheBo test. To 196 
identify genetic variants of CELA3A and CELA3B in the population, we interrogated the Exome 197 
Variant Server database of the NHLBI Exome Sequencing Project. When considering missense 198 
variants only with an allele frequency above 1%, we found one CELA3A variant (G241A) and 199 
five CELA3B variants (W79R, Q134L, I209V, R210H and A241G). See Table 1 in reference 200 
[33] for further details. The occurrence of CELA3A variant G241A and CELA3B variant A241G 201 
was also confirmed by our recent genetic study in a Hungarian population [25]. To evaluate 202 
whether common genetic variants of CELA3A and CELA3B might alter the performance of the 203 
ScheBo test, we purified these six variants and tested their detection in the ELISA assay. With 204 
the exception of the CELA3B W79R variant, none of the variants had an appreciable effect on 205 
signal development (Figure 4). Variant W79R was detected on average 1.4-fold (range 1.2 – 1.5-206 
fold) better than wild-type CELA3B over the concentration range tested. However, considering 207 
that in most carriers the variant is heterozygous, this difference should have no meaningful 208 
impact on the clinical interpretation of the ScheBo test results. 209 
Glu154 in CELA3B is a critical determinant of recognition by the ScheBo test. CELA3A 210 
and CELA3B share 92% identity at the amino-acid level yet CELA3B is detected circa 4-fold 211 
better than CELA3A by the ELISA assay. To identify the reason for this difference, we aligned 212 
the two isoforms (Figure 5A) and then individually mutated all divergent amino-acid positions in 213 
CELA3B to the corresponding CELA3A amino acid. Positions where differences occurred in 214 
neighboring amino acids were mutated en bloc. Overall 11 new CELA3B mutants were 215 
constructed and tested. For these qualitative screening experiments we used conditioned media 216 
of HEK 293T cells transfected with the mutant constructs. Remarkably, mutant E154K gave no 217 
ELISA signal whatsoever while all other mutants were robustly detected with some variations in 218 
signal yield (Figure 5B). Since the mutations may alter secretion and enzymatic activity of 219 
CELA3B, we also verified the expression of all mutants by SDS-PAGE and Coomassie staining 220 
(not shown) and by direct activity measurements after activation with trypsin. As shown in 221 
Figure 5C, all mutants, including E154K, exhibited measurable elastase activity and for the 222 
majority of mutants activity was comparable or even higher than that of the wild-type CELA3B. 223 
The higher activity of mutants S77R,S78D,W79L and D89N,R90L was due to higher elastase 224 
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amounts secreted to the conditioned medium (not shown) and this was also consistent with the 225 
stronger ELISA signal (Figure 5B). Similarly, mutant A241G was secreted to higher levels (not 226 
shown) and produced a higher ELISA signal but this change was not obvious in the activity 227 
measurement as this mutation decreases catalytic activity of CELA3B [25]. Taken together, this 228 
initial screen conclusively identified Glu154 in CELA3B as a major determinant of recognition 229 
by the ScheBo test. 230 
 To confirm the importance of Glu154, we purified the E154K mutant and compared 231 
detection to wild-type CELA3B over a 20-200 pM concentration range. No signal was obtained 232 
with the mutant (Figure 6A). The ScheBo test uses a sandwich assay format with separate 233 
capturing and detection antibodies directed at different regions of the elastase molecules (see 234 
Figure 1). To ascertain whether the defect with the E154K mutant is at the level of capturing or 235 
detection, we eliminated the capturing step by immobilizing wild-type and mutant CELA3B to 236 
nickel plates (Ni-NTA HisSorb plate, Qiagen, Valencia, CA) via their His-tag. Under these assay 237 
conditions both elastase forms were detected comparably, indicating that mutation E154K 238 
interferes with the capturing step in the ELISA protocol (Figure 6B). Finally, structural modeling 239 
indicated that Glu154 is located on the surface of CELA3B far removed from the active site 240 
(Figure 6C). 241 
Mutations of Lys154 and nearby Arg179 improve detection of CELA3A. The experiments 242 
presented above strongly indicated that detection of CELA3A should be improved by changing 243 
the Lys154 residue to Glu. Surprisingly, however, when the CELA3A mutant K154E was 244 
purified and tested, no improvement in detection was observed over wild-type CELA3A (Figure 245 
7A). To explain these puzzling observations, we speculated that the presence of another 246 
divergent amino-acid that lies in proximity interferes with the recognition of Glu154 in the 247 
CELA3A K154E mutant. Inspection of the CELA3B structural model indicated that amino acid 248 
179, which is Arg in CELA3A and Leu in CELA3B, might be important in this regard (see 249 
Figure 6C). Indeed, when mutations K154E and R179L were introduced simultaneously in 250 
CELA3A, the ELISA signal was increased by about 2.5-fold and approximated that of CELA3B 251 
(Figure 7B). 252 
 253 
DISCUSSION 254 
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In the present study, we evaluated the isoform specificity of the ScheBo Pancreatic Elastase 1 255 
Stool Test. The clinical utility of the fecal elastase test in the evaluation of pancreatic 256 
insufficiency has been well established and it has become widely used for routine indirect testing 257 
of pancreatic function [7, 8, 12, 15, 18, 19, 20, 23, 30, 32]. Although limitations were also 258 
indicated by some studies [1, 20], the test gained popularity because it is non-invasive, relatively 259 
rapid, unaffected by pancreatic enzyme replacement therapy and clearly superior to the 260 
previously used indirect test that measured fecal chymotrypsin activity. Somewhat surprisingly, 261 
the exact molecular targets of this ELISA assay have not been characterized; it has been unclear 262 
which elastase isoform(s) the test detects, and whether other homologous pancreatic proteinases 263 
interfere with the assay. The misnomer used in the test’s commercial name adds to the 264 
uncertainty as to what exactly it measures. As discussed in the introduction of this paper, CELA1 265 
is not expressed in the human pancreas and the test’s name in all likelihood refers to one of the 266 
several historic names used for CELA3B in the article published by Largman et al. in 1976 [17]. 267 
Thus, we expected the test would detect CELA3B; yet the vexing questions remained whether 268 
the 92% identical CELA3A isoform was equally well detected and whether natural genetic 269 
variants of CELA3A and CELA3B affected test performance. Taking advantage of developments 270 
in the genomic sequencing and annotation of human digestive enzymes, we used well-defined 271 
recombinant preparations of human elastases, chymotrypsins and trypsins to characterize the 272 
specificity of the ScheBo test. 273 
 Our findings confirmed that the primary target of the test is CELA3B, however, CELA3A is 274 
also detected, approximately 4-fold weaker than CELA3B. Importantly, CELA2A, 275 
chymotrypsins CTRB1, CTRB2, CTRC, CTRL1 and trypsins PRSS1, PRSS2, PRSS3 produced 276 
minimal or no signal in this ELISA assay. Sziegoleit (1984) measured CELA3B levels as 4-6% 277 
of total juice protein [36] and other studies indicated that mRNA and protein levels for the two 278 
CELA3 isoforms are grossly comparable [31, 42]. However, there is no information available on 279 
how the expression of CELA3A and CELA3B in the pancreas might vary under different 280 
physiological and pathological conditions. It is intriguing to speculate that test performance 281 
might be affected by changes in the CELA3 isoform ratio. For this reason, development of a test 282 
that specifically detects CELA3B without any cross-reactivity with CELA3A could potentially 283 
offer a better diagnostic tool. 284 
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 Elastases are secreted as inactive precursors (zymogens) by the pancreas and these 285 
proelastases become activated in the duodenum by trypsin. Proelastases can also suffer autolysis 286 
due to their intrinsic zymogen activity or by active elastases [33]. The most prominent autolytic 287 
cleavage takes place at the Val30-Asn31 peptide bond in CELA3B (and to a lesser extent at the 288 
Val30-His31 peptide bond in CELA3A) resulting in a catalytically inactive elastase species [11, 289 
33]. We compared test performance on all molecular forms of CELA3B and found no difference 290 
in detection efficiency, indicating that test results are unaffected by the activation state or the 291 
degree of autolysis of secreted elastases. 292 
 Another potentially confounding factor is the occurrence of natural genetic variants of the 293 
CELA3 isoforms that might react differently with the ELISA assay than the wild-type targets. 294 
The test is based on the binding of elastase to two monoclonal antibodies (see Figure 1) and 295 
genetic variants can alter the surface epitopes where these antibodies bind, resulting in altered 296 
detection efficiency. We characterized the effect on test performance of all genetic variants of 297 
CELA3A and CELA3B, which occur at or above 1% frequency in the population and found no 298 
clinically meaningful changes. Only one variant, CELA3B W79R, exhibited increased detection 299 
by approximately 1.4-fold, which should be inconsequential in heterozygous carriers. Our studies 300 
do not rule out the possibility that rare or private genetic variants in certain patients may interfere 301 
with the test, however, for the large majority of the population the ScheBo test should not be 302 
affected by common genetic variants in the CELA3 isoforms. 303 
 We performed limited epitope mapping to identify amino-acids that are responsible for the 304 
preferential detection of CELA3B over CELA3A by the ScheBo test. We identified Glu154 in 305 
CELA3B, which is Lys in CELA3A, as a key determinant of recognition by the capturing 306 
monoclonal antibody. Mutation E154K in CELA3B abolished detection by the ELISA assay. 307 
Surprisingly, however, the opposite mutation K154E in CELA3A did not improve detection by 308 
the test and simultaneous mutation of the nearby Arg179 to Leu (R179L) was required to achieve 309 
signal levels that were comparable to those of CELA3B. 310 
 Position 154 is located within a potential N-glycosylation site and we considered the 311 
possibility that the side-chain of amino-acid 154 may alter glycosylation and thereby affect 312 
antibody recognition. N-linked glycosylation occurs on Asn residues in Asn-Xaa-Ser/Thr 313 
sequons where Xaa can be any amino acid except for Pro. Importantly, however, if the amino 314 
acid following the sequon is a Pro, N-glycosylation is inhibited [22]. In CELA3A the sequon 315 
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Asn153-Lys154-Thr155 and in CELA3B the sequon Asn153-Glu154-Thr155 are followed by 316 
Pro156, indicating that Asn153 is unlikely to undergo glycosylation in either isoform. This 317 
notion is consistent with earlier studies which characterized the glycosylation of CELA3B and 318 
found a single N-glycosylation site at Asn114 [45]. Finally, although data are not shown, we 319 
observed no change in the detection of CELA3A and CELA3B by the ScheBo test after 320 
treatment with peptide-N-glycosidase F (PNGase F). 321 
 In addition to the ScheBo test which utilizes monoclonal antibodies, another clinical test has 322 
been developed and commercialized by BIOSERV Diagnostics GmbH (Rostock, Germany) 323 
which is based on detection by polyclonal antibodies against elastase 1 [12, 13, 23, 30]. A recent 324 
study characterized the isoform specificity of the BioServ test and found that CELA3A is a target 325 
while CELA2A is not detected, however, other pancreatic proteinases were not evaluated in a 326 
comprehensive manner [44]. 327 
 In summary, we characterized the molecular targets of the ScheBo Pancreatic Elastase 1 328 
Stool Test and demonstrated that it predominantly measures CELA3B but also detects CELA3A 329 
with lower efficacy. Other pancreatic proteinases or genetic variants of the CELA3 isoforms 330 
have no appreciable impact on test performance. 331 
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LEGENDS TO FIGURES 458 
Figure 1. Schematic diagram of elastase detection by the sandwich ELISA method of the 459 
ScheBo Pancreatic Elastase 1 Stool Test. See Methods for details. 460 
 461 
Figure 2. Detection of human pancreatic serine proteinases by the ScheBo Pancreatic Elastase 1 462 
Stool Test. Proteinases were expressed recombinantly and purified as described in Methods. 463 
CELA3A and CELA3B were tested at 0.1 nM final concentration whereas all other proteinases 464 
were tested at 1 nM concentration. For CTRL1, conditioned medium diluted 1000-fold was used. 465 
Mean values with SD from three measurements are shown. 466 
 467 
Figure 3. Detection of CELA3 isoforms by the ScheBo Pancreatic Elastase 1 Stool Test. (A) 468 
Comparison of test performance on proelastases versus active elastases in the 20-200 pM 469 
concentration range. (B) Detection of autolyzed forms of CELA3B. The inset demonstrates the 470 
autolytic cleavage sites in the N-terminal part of CELA3B. Assays were performed in duplicate 471 
and both data points were plotted. 472 
 473 
Figure 4. Detection of naturally occurring CELA3A and CELA3B variants by the ScheBo 474 
Pancreatic Elastase 1 Stool Test. Wild-type CELA3A, CELA3B and the indicated variants were 475 
purified and assayed in the 20-200 pM concentration range. Assays were performed in duplicate 476 
and both data points were plotted. 477 
 478 
Figure 5. The effect of amino-acid differences between CELA3A and CELA3B on detection by 479 
the ScheBo Pancreatic Elastase 1 Stool Test (A) Alignment of the amino-acid sequences of the 480 
two human CELA3 isoforms. The active enzymes are shown; numbering starts with the initiator 481 
methionine of the pre-proelastases. Differences are underlined and emboldened. (B) ELISA of 482 
CELA3B mutants carrying substitutions with the corresponding CELA3A amino acids. HEK 483 
293T cells were transfected with the indicated constructs and conditioned medium was collected 484 
after 48 h. Elastase was assayed using 1000-fold diluted conditioned medium by the ScheBo test. 485 
See Methods for further details. (C) Elastase activity of CELA3B mutants measured in the 486 
conditioned medium after activation with trypsin. See Methods for experimental details. Mean 487 
values with SD from three experiments are shown. 488 
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 489 
Figure 6. Detection of CELA3B mutant E154K by the ScheBo Pancreatic Elastase 1 Stool Test. 490 
(A) Purified wild-type and E154K mutant CELA3B were assayed over the 20-200 pM 491 
concentration range. (B) Purified wild-type and E154K mutant CELA3B were immobilized 492 
through their C-terminal His-tags to Ni-NTA HisSorb Plates (Qiagen) and detected with the 493 
biotinylated antibody–streptavidin–peroxidase complex form the ScheBo test. Assays were 494 
performed in duplicate and both data points were plotted. (C) Structural model of human 495 
CELA3B indicating the positions of Glu154 (green) and nearby Leu179 (red). Also shown for 496 
reference are the residues of the catalytic triad (magenta). The structural model for active 497 
CELA3B was generated by the SWISS-MODEL protein structure homology-modeling server [2] 498 
using porcine elastase as template (PDB file 3UOU). The image was rendered with PyMOL 499 
(Schrödinger, Cambridge, MA). 500 
 501 
Figure 7. Detection of CELA3A mutant K154E and double mutant K154E,R179L by the 502 
ScheBo Pancreatic Elastase 1 Stool Test. Wild-type CELA3A, CELA3B and the indicated 503 
CELA3A variants were purified and assayed in the 20-200 pM concentration range. Assays were 504 
performed in duplicate and both data points were plotted. 505 
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